202 278

Cited 6 times in

Safety and Efficacy of Conversion from Twice-Daily Tacrolimus to Once-Daily Tacrolimus One Month after Transplantation: Randomized Controlled Trial in Adult Renal Transplantation

 Chang-Kwon Oh  ;  Kyu Ha Huh  ;  Jong Soo Lee  ;  Hong Rae Cho  ;  Yu Seun Kim 
 YONSEI MEDICAL JOURNAL, Vol.55(5) : 1341-1347, 2014 
Journal Title
Issue Date
Adult ; Drug Administration Schedule ; Female ; Graft Rejection/drug therapy ; Graft Rejection/prevention & control ; Humans ; Immunosuppressive Agents/administration & dosage* ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Kidney Transplantation* ; Male ; Middle Aged ; Safety ; Tacrolimus/administration & dosage* ; Tacrolimus/adverse effects ; Tacrolimus/therapeutic use
Acute rejection ; efficacy ; extended-release tacrolimus ; kidney transplantation ; safety
PURPOSE: The purpose of this study was to compare once-daily tacrolimus with twice-daily tacrolimus in terms of safety, efficacy, and patient satisfaction. MATERIALS AND METHODS:This prospective, randomized, open-label, multicenter study was conducted at three institutes. Patients in the investigational group were converted from tacrolimus twice daily to the same dose of extended-release tacrolimus once daily at 1 month post-transplantation, while patients in the control group were maintained on tacrolimus twice daily. The efficacies, safeties, and patient satisfaction for the two drugs at 6 months post-transplantation were compared. RESULTS:Sixty patients were enrolled and randomized to the investigational group (28 of 29 patients completed the study) or the control group (26 of 31 patients completed the study). At 6 months post-transplantation, composite efficacy failure rates including the incidences of biopsy-confirmed acute rejection in the investigational and control groups were 0% and 10.7%, respectively; patient survival was 100% in each group. No difference in estimated glomerular filtration rate values were observed at 6 months post-transplantation (p=0.97). The safety and satisfaction profile (immunosuppressant therapy barrier scale) of once-daily tacrolimus was comparable with that of twice-daily tacrolimus (p=0.35). CONCLUSION:Conversion from twice-daily tacrolimus to once-daily tacrolimus one month after transplantation is safe and effective.
Files in This Item:
T201402171.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Yu Seun(김유선) ORCID logo https://orcid.org/0000-0002-5105-1567
Huh, Kyu Ha(허규하) ORCID logo https://orcid.org/0000-0003-1364-6989
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.